Form 4: Bristol Myers Squibb CEO Transfers Shares to Spousal Lifetime Access Trust

Bristol Myers Squibb CEO Christopher S. Boerner has reported a transfer of 62,720 shares of common stock to a Spousal Lifetime Access Trust (SLAT) as part of an estate planning transaction.

Summary

• Christopher S. Boerner, Chief Executive Officer and Director of Bristol Myers Squibb Co (BMY), filed a Form 4 statement regarding changes in beneficial ownership.
• On June 3, 2025, Mr. Boerner disposed of 62,720 shares of Bristol Myers Squibb Common Stock, $0.10 par value, from his direct ownership.
• Concurrently, 62,720 shares of the same common stock were acquired indirectly through a Spousal Lifetime Access Trust (SLAT).
• The transaction code 'G' indicates a gift, and the price per share for this transfer was $0.
• Following these reported transactions, Mr. Boerner's direct beneficial ownership stands at 62,719 shares, while his indirect beneficial ownership through the Trust is 62,720 shares.
• The transfer represents a change in the form of ownership (from direct to indirect via trust) rather than a sale or purchase for value.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider filing for a non-market transaction (gift to a trust) that does not reflect on the company's operational or financial performance.

Positives

• The transaction reflects a common estate planning strategy, which can be a prudent financial move for individuals.

Negatives

• The transaction does not involve a sale of shares into the open market, thus it does not directly indicate a lack of confidence in the company's future by the CEO.

Risks

• No specific risks to the company's operations or financial health are indicated by this routine insider ownership filing.

Future Outlook

This SEC Form 4 filing pertains to an insider's personal stock ownership changes and does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Management Comments

• The reporting person transferred shares to a Spousal Lifetime Access Trust (SLAT).

Industry Context

This filing is a routine disclosure of an insider's personal stock transaction and does not provide insights into broader industry trends or competitive dynamics within the pharmaceutical sector. Such transfers are common for high-net-worth individuals for estate planning purposes.

Comparison to Industry Standards

• This type of transaction (transfer to a trust for estate planning) is a standard practice among executives and high-net-worth individuals across various industries, including pharmaceuticals. It does not reflect on the company's operational performance or competitive standing.

Related Party Transactions

• The transfer of shares to a Spousal Lifetime Access Trust (SLAT) can be considered a related party transaction as it involves a trust for the benefit of the reporting person's spouse.

Stakeholder Impact

• Shareholders: Minimal to no direct impact as this is a change in the form of ownership for an insider, not a sale into the market.
• Employees, Customers, Suppliers, Creditors: No discernible impact on these stakeholders as the transaction is a personal estate planning matter for the CEO.

Next Steps

• No specific company-related next steps are indicated by this personal insider transaction filing.

Key Dates

Keywords

Bristol Myers Squibb, BMY, SEC Form 4, Insider Transaction, Stock Transfer, Estate Planning, Spousal Lifetime Access Trust, SLAT, Beneficial Ownership, CEO